Sign in to view content

Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients

Franco M. Recchia, MD

Video
Published 2021

Related

BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019
APEX: A Phase II Randomized Clinical Trial Evaluating the Safety andPreliminary Efficacy of X-82 Administered Orally in the Treatment of Exudative AMD
Michael N. Cohen, MD
Updates from the Field
2020
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more